# AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

> **NCT06951503** · PHASE3 · RECRUITING · sponsor: **Akeso** · enrollment: 560 (estimated)

## Conditions studied

- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** AK112
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin and 5-FU
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06951503
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-27
- **Primary completion:** 2027-01-13
- **Final completion:** 2029-01-07
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06951503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06951503, "AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06951503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*